TKT and prostate cancer: Freytag et al. have constructed additional suicide genes (improved yeast CD and mutant SR39 HSV-1 TK) into oncolytic adenovirus, namely Ad5-yCD/mutTKSR39rep-ADP and combined this virus with intensity-modulated radiotherapy (IMRT) in phase I prostate cancer clinical trial [21].